Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

van den Buuse M.

Schizophr Bull. 2010 Mar;36(2):246-70. doi: 10.1093/schbul/sbp132. Epub 2009 Nov 9. Review.

2.

Schizophrenia-relevant behaviors in a genetic mouse model of constitutive Nurr1 deficiency.

Vuillermot S, Joodmardi E, Perlmann T, Ove Ögren S, Feldon J, Meyer U.

Genes Brain Behav. 2011 Jul;10(5):589-603. doi: 10.1111/j.1601-183X.2011.00698.x. Epub 2011 May 30.

3.

Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia.

Lipina TV, Niwa M, Jaaro-Peled H, Fletcher PJ, Seeman P, Sawa A, Roder JC.

Genes Brain Behav. 2010 Oct;9(7):777-89. doi: 10.1111/j.1601-183X.2010.00615.x. Epub 2010 Aug 12.

4.

The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids.

Boucher AA, Hunt GE, Micheau J, Huang X, McGregor IS, Karl T, Arnold JC.

Int J Neuropsychopharmacol. 2011 Jun;14(5):631-43. doi: 10.1017/S146114571000091X. Epub 2010 Aug 12.

PMID:
20701826
5.

Altered N-methyl-D-aspartate receptor function in reelin heterozygous mice: male-female differences and comparison with dopaminergic activity.

van den Buuse M, Halley P, Hill R, Labots M, Martin S.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jun 1;37(2):237-46. doi: 10.1016/j.pnpbp.2012.02.005. Epub 2012 Feb 15.

PMID:
22361156
6.
7.

1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat.

Pietraszek M, Michaluk J, Romańska I, Wasik A, Gołembiowska K, Antkiewicz-Michaluk L.

Neurotox Res. 2009 Nov;16(4):390-407. doi: 10.1007/s12640-009-9097-y. Epub 2009 Aug 1.

PMID:
19649683
8.
9.

Acoustic startle response and sensorimotor gating in a genetic mouse model for the Y1 receptor.

Karl T, Chesworth R, Duffy L, Herzog H.

Neuropeptides. 2010 Jun;44(3):233-9. doi: 10.1016/j.npep.2009.12.008. Epub 2010 Jan 25.

PMID:
20096928
10.

Mutant mouse models: phenotypic relationships to domains of psychopathology and pathobiology in schizophrenia.

O'Tuathaigh CM, Waddington JL.

Schizophr Bull. 2010 Mar;36(2):243-5. doi: 10.1093/schbul/sbq004. Epub 2010 Feb 12. Review.

11.

Prepulse inhibition and genetic mouse models of schizophrenia.

Powell SB, Zhou X, Geyer MA.

Behav Brain Res. 2009 Dec 7;204(2):282-94. doi: 10.1016/j.bbr.2009.04.021. Epub 2009 May 4.

12.

Comprehensive behavioral analysis of ENU-induced Disc1-Q31L and -L100P mutant mice.

Shoji H, Toyama K, Takamiya Y, Wakana S, Gondo Y, Miyakawa T.

BMC Res Notes. 2012 Feb 20;5:108. doi: 10.1186/1756-0500-5-108.

13.

Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats.

Swerdlow NR, Shilling PD, Breier M, Trim RS, Light GA, Marie RS.

Psychopharmacology (Berl). 2012 Dec;224(3):349-62. doi: 10.1007/s00213-012-2758-1. Epub 2012 Jun 15.

PMID:
22700037
14.

Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

O'Tuathaigh CM, Kirby BP, Moran PM, Waddington JL.

Schizophr Bull. 2010 Mar;36(2):271-88. doi: 10.1093/schbul/sbp125. Epub 2009 Nov 24.

15.

Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation.

van den Buuse M, Wischhof L, Lee RX, Martin S, Karl T.

Int J Neuropsychopharmacol. 2009 Nov;12(10):1383-93. doi: 10.1017/S1461145709000388. Epub 2009 Apr 29.

PMID:
19400983
16.

Schizophrenia-relevant behaviours in a genetic mouse model for Y2 deficiency.

Karl T, Chesworth R, Duffy L, Herzog H.

Behav Brain Res. 2010 Mar 5;207(2):434-40. doi: 10.1016/j.bbr.2009.10.029. Epub 2009 Oct 30.

PMID:
19879900
17.

Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine.

Levin R, Calzavara MB, Santos CM, Medrano WA, Niigaki ST, Abílio VC.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1748-52. doi: 10.1016/j.pnpbp.2011.06.003. Epub 2011 Jun 13.

18.

Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.

Meyer U, Spoerri E, Yee BK, Schwarz MJ, Feldon J.

Schizophr Bull. 2010 May;36(3):607-23. doi: 10.1093/schbul/sbn131. Epub 2008 Oct 8.

19.

Behavioral abnormalities in synapsin II knockout mice implicate a causal factor in schizophrenia.

Dyck BA, Skoblenick KJ, Castellano JM, Ki K, Thomas N, Mishra RK.

Synapse. 2009 Aug;63(8):662-72. doi: 10.1002/syn.20643.

PMID:
19360855
20.

Preweaning sensorimotor deficits and adolescent hypersociability in Grin1 knockdown mice.

Moy SS, Nikolova VD, Riddick NV, Baker LK, Koller BH.

Dev Neurosci. 2012;34(2-3):159-73. Epub 2012 May 8.

Items per page

Supplemental Content

Write to the Help Desk